Metabolic & weight · Peptide medicine
Also known as Mounjaro, Zepbound
A GIP and GLP-1 receptor agonist used in FDA-approved products for specific metabolic and weight-related uses. Brand labels are not interchangeable.[1]
Human studies and labelled product evidence are available in specific contexts. This is not a ranking of suitability or a guarantee that every product or use has the same evidence.
Reviewed Jul 22, 2026 · U.S.-focused reference profile
Read the context, not only the compound name. Evidence and status can change with the form, route, population, and use. This profile does not assess individual suitability.
Orientation
Start with identity and research context. Similar names do not establish equivalent products or evidence.
Published research or product contexts. These are not personal indications.
Evidence can change with chemical form, formulation, route, ingredients, and manufacturing. A brand, salt, fragment, or cosmetic ingredient may not represent the same evidence.
What is known
Human studies and labelled product evidence are available in specific contexts. This is not a ranking of suitability or a guarantee that every product or use has the same evidence. This is a description, not a rating or recommendation.
GLP-1, metabolic and weight-management
Large randomized clinical programs in FDA labeling support tirzepatide products for their approved uses. Results are tied to the studied populations and branded products.
Rare or long-latency risks may become clearer with broader use. Mounjaro and Zepbound have different approved contexts, and evidence for approved products does not validate unapproved compounded or mislabeled products.
Nonclinical studies supported the pharmacology and safety assessment. Rodent thyroid C-cell tumor findings described in labeling have uncertain human relevance.[1]
More human evidence does not automatically transfer to a different product, route, population, or purpose. Limited evidence does not prove no biological activity; it means the relevant clinical question is not established by the reviewed material.
What needs caution
Known published concerns and unanswered questions are kept separate so absence of evidence is never presented as reassurance.
Labeled risks include gastrointestinal reactions, pancreatitis, gallbladder disease, kidney injury related to volume depletion, hypoglycemia with some medicines, hypersensitivity, and a boxed warning concerning thyroid C-cell tumors.
The cited product label describes risks for a specific approved product and use. It is not a complete guide to every product or individual situation.Source [1]Rare or long-latency risks may become clearer with broader use. Mounjaro and Zepbound have different approved contexts, and evidence for approved products does not validate unapproved compounded or mislabeled products.
The answer can change with the product, formulation, route, population, duration, and use being discussed.Source [1]Common effects, important warnings, product-quality concerns, and evidence gaps are different kinds of information. A risk in one product label may not apply to every formulation; an uncertainty proves neither safety nor harm.
Match the product
Form describes the specific product; route describes how it reaches the body. These are sourced descriptions, not instructions.
Prescription subcutaneous injection products are marketed under separate applications and indications.
Routes shown apply only to the named published or investigational formulation; they are not instructions for use.
U.S. product context
At least one FDA-approved product exists, but approval applies only to the named product, formulation, route, population, and use in its label.
Status applies to a product, formulation, route, population, and use. It does not apply to a name in the abstract.
Tirzepatide is FDA approved in product-specific contexts, including Zepbound for labeled chronic weight-management and other labeled uses. Approval is product- and indication-specific.
Specific form or route not separately published in this record.View sourceTake it forward
Organize a conversation with a qualified professional without creating a treatment recommendation, dose, or protocol.
Organize an existing plan
PeptideGrid can help you organize a schedule and keep dose records together for a plan you already follow. It does not recommend a dose, schedule, or treatment.
Trace the record
Each source supports the section that cites it; publication does not imply endorsement or suitability.
ZEPBOUND prescribing information
DailyMed. ZEPBOUND (tirzepatide) prescribing information. Revised May 2026.
National Library of Medicine / Eli Lilly · Published May 6, 2026 · Accessed Jul 22, 2026 · Prescribing information
Open sourceIdentity, human evidence, laboratory and animal findings, risks, uncertainty, and U.S. product status are shown separately. Missing information stays marked as unpublished instead of being inferred.
